HDAC9 and breast cancer: The UPR is reported to confer breast cancer cells with resistance to radiation therapy [67], tamoxifen [36], paclitaxel, vinca alkaloids [68], cisplatin [69], doxorubicin [9], histone deacetylase (HDAC) inhibitors [62], and microtubule interfering agents [70].